Target ACE2, Spike protein
Aus coViki
(Unterschied zwischen Versionen)
K |
|||
| (25 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
ACE2; any specific functions of spike protein; | ACE2; any specific functions of spike protein; | ||
| + | {{up|PHA antivirals by mechanism}} | ||
| + | {{up|PHA pharmacophore by screened target}} | ||
| − | {{ | + | {{qt|PHA ACE2 Structure spike-ace2}} |
| − | {{ | + | {{qt|PHA ACE2 in target tissues}} |
| − | {{ | + | {{qt|PHA ACE2 regulation of ACE2}} |
| − | {{ | + | {{qt|PHA ACE2 drug design}} spike RBD |
| − | {{ | + | {{qt|PHA SCR spike protein general aspects}} spike any target |
| − | {{ | + | {{qt|PHA ACE2 amplification}} |
| − | {{ | + | {{qt|PHA ACE2 soluble ace2}} |
| − | {{ | + | {{qt|PHA Angiotensin(1-7)}} |
| − | {{ | + | {{qt|PHA Angiotensin II}} |
| − | {{ | + | {{qt|RSP - On RAS drugs}} |
| + | {{qt|MOD ACE2 transgenic mice}} | ||
| + | {{qt|MOD Zebrafish}} | ||
| + | {{qt|PHA ACE2 ace2 species specificity clade specificity}} | ||
| − | {{tp|p= | + | |
| − | {{tp|p= | + | {{ttp|p=32449939|t=2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.|pdf=|usr=007}} |
| + | {{tp|p=32582574|t=2020. ACE2, Much More Than Just a Receptor for SARS-COV-2.|pdf=|usr=011}} | ||
| + | {{tp|p=32738617|t=2020. ACE2 Co-evolutionary Pattern Suggests Targets for Pharmaceutical Intervention in the COVID-19 Pandemic.|pdf=|usr=018}} | ||
| + | {{tp|p=32602627|t=2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=011}} | ||
| + | {{tp|p=32585135|t=2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.|pdf=|usr=010}} | ||
| + | {{tp|p=32747721|t=2020. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.|pdf=|usr=018}} | ||
| + | {{tp|p=32913581|t=2020. Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike.|pdf=|usr=019}} | ||
Aktuelle Version vom 27. April 2021, 19:39 Uhr
ACE2; any specific functions of spike protein;
| PHA antivirals by mechanism |
| PHA pharmacophore by screened target |
| PHA ACE2 Structure spike-ace2 |
| PHA ACE2 in target tissues |
| PHA ACE2 regulation of ACE2 |
| PHA ACE2 drug design |
| PHA SCR spike protein general aspects |
| PHA ACE2 amplification |
| PHA ACE2 soluble ace2 |
| PHA Angiotensin(1-7) |
| PHA Angiotensin II |
| RSP - On RAS drugs |
| MOD ACE2 transgenic mice |
| MOD Zebrafish |
| PHA ACE2 ace2 species specificity clade specificity |
| 32449939 2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection. |
32582574 2020. ACE2, Much More Than Just a Receptor for SARS-COV-2.
32738617 2020. ACE2 Co-evolutionary Pattern Suggests Targets for Pharmaceutical Intervention in the COVID-19 Pandemic.
32602627 2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.
32585135 2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
32747721 2020. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19.
32913581 2020. Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike.
